Overall market sentiment has been high on Aprea Therapeutics Inc (APRE) stock lately. APRE receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With APRE Stock Today?
Aprea Therapeutics Inc (APRE) stock is trading at $6.97 as of 1:31 PM on Wednesday, Feb 3, a gain of $0.74, or 11.88% from the previous closing price of $6.23. The stock has traded between $6.30 and $7.50 so far today. Volume today is high. So far 4,059,116 shares have traded compared to average volume of 2,381,309 shares.
To see InvestorsObserver's Sentiment Score for Aprea Therapeutics Inc click here.
More About Aprea Therapeutics Inc
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
Click Here to get the full Stock Score Report on Aprea Therapeutics Inc (APRE) Stock.
